Boston Scientific's heart failure lead:
This article was originally published in Clinica
Executive Summary
The Acuity Steerable left ventricular lead developed by Boston Scientific has gained Japanese approval, and may now be used with cardiac resynchronisation therapy (CRT) devices. The lead has a deflectable tip to aid placement in difficult-to-access branch vessels on the left side of the heart. It also provides physicians with four configurations for stimulating the left side of the heart, Boston said, which allows physicians to change the stimulation site noninvasively after implantation. The lead also received reimbursement approval from the Japanese National Health Insurance System. Natick, Massachusetts-based Boston plans to launch the product immediately in Japan.